Research, Collaboration and License Agreements - Additional Information (Details)	1 Months Ended						3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Oct. 31, 2020 USD ($)	Aug. 31, 2020 USD ($)	Apr. 30, 2020 Product	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 shares	Oct. 29, 2020 USD ($)	Nov. 30, 2019 shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock, shares issued | shares							186,960,193		186,960,193				63,207,507
Research and development							$ 11,791,000	$ 16,774,000	$ 44,096,000	$ 78,462,000
TSHA-120
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional milestone payments									0
Upfront payment			$ 5,500,000
Clinical, regulatory and commercial milestones to be received			$ 19,300,000
License Agreement for CLN7
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional milestone payments									0
Payment of one-time upfront license fee		$ 300,000
License agreement regulatory related milestones maximum amount payable		7,700,000
License agreement sales-related milestones maximum amount payable		$ 7,500,000
UT Southwestern Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Preclinical activities period under sponsored research agreements						2 years
Minimum licensed product to develop obtain regulatory approval for and commercialize | Product						1
Common stock, shares issued | shares															2,179,000
Percentage of fully diluted common stock shares outstanding															20.00%
Abeona CLN1 Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fee payment					$ 3,000,000.0
Purchase of clinical materials and reimbursement incurred development costs				$ 4,000,000.0
Research and development											$ 3,000,000	$ 7,000,000.0
Abeona CLN1 Agreements | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License and inventory purchase agreement regulatory related milestones payment					26,000,000.0
License and inventory purchase agreement sales related milestones payment					$ 30,000,000.0
Abeona | Rett Research and Development Activities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional milestone payments									0
Research and development									$ 3,500,000	$ 1,000,000.0
Payment of one-time upfront license fee												$ 3,000,000.0
Regulatory milestone fee paid	$ 1,000,000.0
Abeona | Maximum | Rett Research and Development Activities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory related milestones obligation payable														$ 26,500,000
Sale-related milestones per licensed product and royalties on net sales of licensed products payable														$ 30,000,000.0